N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Names and Identifiers

Name	Gliquidone
Synonyms	ardf26 ardf26se Glurenorm 251-463-2 Gliquidone GLIQUIDONE Gliquidone Tablets ,4-dimethyl-1,3-dioxo-2(1h)-isoquinolinyl)ethyl)- benzenesulfonamide,n-((cyclohexylamino)carbonyl)-4-(2-(3,4-dihydro-7-methoxy-4 N-(Cyclohexylcarbamoyl)-4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisochinolin-2(1H)-yl)ethyl]benzolsulfonamid N-(Cyclohexylcarbamoyl)-4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]benzenesulfonamide N-(Cyclohexylcarbamoyl)-4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]benzenesulfonamide N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide
CAS	33342-05-1
EINECS	251-463-2
InChI	InChI=1/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Physico-chemical Properties

Molecular Formula	C27H33N3O6S
Molar Mass	527.63
Density	1.34±0.1 g/cm3(Predicted)
Melting Point	179 °C
Solubility	DMSO : 50 mg/mL (94.76 mM; Need ultrasonic);H2O : < 0.1 mg/mL (insoluble)
Appearance	White powder
Color	White to Almost white
Merck	14,4443
pKa	5.12±0.10(Predicted)
Storage Condition	Inert atmosphere,Room Temperature
Refractive Index	1.624
MDL	MFCD00631870
Use	Hypoglycemic agents for the treatment of non-insulin-dependent diabetes mellitus

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Risk and Safety

Safety Description	24/25 - Avoid contact with skin and eyes.
RTECS	DB1584250
HS Code	29147000

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Reference

Reference

1. Li Mengying, Zhang Rui, Yang Min, Shao Fuping, Xu Huihui, Yin Dengke. Effects of Danshen injection on pharmacokinetic parameters and intestinal absorption characteristics of gliquidone in diabetic rats [J]. Journal of Anhui University of Traditional Chinese Medicine, 2019, 38(05):67-70.

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Standard

Authoritative Data Verified Data

This product is 1-cyclohexyl-3-[ [p-[2-(3, 4-dihydro-7-methoxy-4, 4-dimethyl-1, 3-dioxo-2 (1H)-isoquinolyl) ethyl] phenyl] sulfonyl] urea. The content of C27H33N306S shall be 98.0% ~ 102.0% calculated as dry product.

Last Update：2024-01-02 23:10:35

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Trait

Authoritative Data Verified Data

This product is white crystal or crystalline powder; Odorless.
This product is soluble in chloroform, slightly soluble in acetone, slightly soluble in ethanol or methanol, and almost insoluble in water.

melting point

The melting point of this product (General 0612) is 178~182°C.

Last Update：2022-01-01 15:36:15

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Differential diagnosis

Authoritative Data Verified Data

take about 10 mg of this product, add 5 drops of phenylhydrazine, heat until the solution becomes clear, and let it cool. Add 0.5ml of ammonia test solution, 10% ml of nickel sulfate solution and 1ml of chloroform, and shake vigorously, standing, the lower solution should become purple-red.
in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 1097).

Last Update：2022-01-01 15:36:16

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Exam

Authoritative Data Verified Data

chloride

take 2.0g of this product, add 100ml of water, boil, to the remaining about 50ml, quickly let cool, filter, add water to the filtrate to make 50ml, take 25ml, inspection according to law (General rule 0801 ), compared with the standard sodium chloride solution 7.0ml of the control solution, not more concentrated (0.007%).

sulfate

take 25ml of the filtrate remaining under the chloride check item and check it according to law (General rule 0802). Compared with the control solution made of 0.02% of standard potassium sulfate solution, it should not be more concentrated ().

Related substances

take the right amount of this product, precision weighing, plus mobile phase ultrasound to dissolve and dilute the solution containing about 2mg per 1ml, filtering, filtrate as a test solution; take 1ml accurately, put it in a 100ml measuring flask, dilute it to the scale with mobile phase, and use it as a control solution. Take an appropriate amount of isoquinoline reference substance, and weigh it accurately, the mobile phase was added to dissolve and dilute to prepare a solution containing about lOug per 1ml as a control solution. According to the chromatographic conditions under the content determination item, 20ul of the test solution, the control solution and the reference solution are respectively injected into the liquid chromatograph, the chromatogram was recorded to 2 times of the retention time of the main component peak. If there is an impurity peak in the chromatogram of the test solution that is consistent with the retention time of the isoquinoline substance, the peak area shall be calculated according to the external standard method, and the isoquinoline substance shall not exceed 0.75%; the sum of the peak areas of other impurities shall not be greater than the main peak area of the control solution (1.0%).

loss on drying

take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).

ignition residue

take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.

Heavy metals

The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).

Last Update：2022-01-01 15:36:17

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Content determination

Authoritative Data Verified Data

measured by high performance liquid chromatography (General 0512).

chromatographic conditions and system suitability test

silica gel bonded with OCTA alkyl silane as filler; Ammonium dihydrogen phosphate solution (take 1.725g of ammonium dihydrogen phosphate, add water to dissolve 3.5±0.1, adjust pH to with phosphoric acid)-acetonitrile (3:5) the detection wavelength was 310Nm. Appropriate amounts of gliquidone control and isoquinoline control were dissolved and diluted with mobile phase ultrasound to prepare 50ug solutions each in 1 ml, and 20ul was injected into the liquid chromatograph, the number of theoretical plates shall not be less than 2000 calculated by gliquidone peak, and the separation degree between gliquidone peak and isoquinoline peak shall meet the requirements.

assay

take this product, precision weighing, plus mobile phase ultrasound to dissolve, cool, and quantitative dilution made in each lml containing about 0.lmg solution was used as the test solution, and 20ul was injected into the liquid chromatograph with precision, and the chromatogram was recorded. Another gliquidone reference substance was taken and determined by the same method. According to the external standard method to calculate the peak area, that is.

Last Update：2022-01-01 15:36:17

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Category

Authoritative Data Verified Data

hypoglycemic drugs.

Last Update：2022-01-01 15:36:18

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Storage

Authoritative Data Verified Data

sealed storage.

Last Update：2022-01-01 15:36:18

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Gliquidone Tablets

Authoritative Data Verified Data

This product contains gliquidone (C27H33N306S) should be 95.0% ~ 105.0% of the label.

trait

This product is white tablet.

identification

take an appropriate amount of fine powder of this product, add an appropriate amount of mobile phase, ultrasonic dissolve and dilute gliquidone to make about 0.1 mg of the solution was filtered, and the filtrate was used as the test solution; Another gliquidone control substance was taken, dissolved and diluted by adding mobile phase ultrasound to make about 0 per 1 ml. 1 mg solution, as a control solution. According to the chromatographic conditions under the relevant substances inspection item, 20ul of the test solution and the reference solution are respectively injected into the liquid chromatograph, and the chromatograms are recorded, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the control solution.
take an appropriate amount of fine powder of this product (about 20mg equivalent to gliquidone), grind it finely, add 10ml of methanol, grind it and dissolve it, filter it, evaporate the filtrate to dryness, and dry the residue under reduced pressure, determination according to law (General rule 0402). The infrared absorption spectrum of this product should be consistent with the spectrum of the control (Spectrum set 1097 figure).

examination

relevant substances: take an appropriate amount of fine powder of this product, precisely weigh it, add an appropriate amount of mobile phase, and ultrasonically dissolve and dilute gliquidone to make a solution containing about 2mg per 1ml, and filter it, the filtrate was used as the test solution; 1ml of the sample was accurately measured and placed in a 100ml measuring flask, diluted to the scale with mobile phase, and then shaken to serve as the control solution, A solution containing about 1 ug per 1ml was prepared using the mobile phase as a control solution. If there is an impurity peak in the chromatogram of the test solution with the same retention time as the isoquinoline peak, the peak area shall be calculated according to the external standard method, isoquinoline shall not exceed 1.0% of the labeled amount of gliquidone, and the sum of the peak areas of other impurities shall not be greater than 1.5 times (1.5%) of the main peak area of the control solution.
dissolution dissolution of this product, according to the dissolution and release determination method (General rule 0931 second method), with phosphate buffer solution (take disodium hydrogen phosphate 71.2g, add water 1000ml to dissolve, adjust the pH value to 10% with 8.5 citric acid solution) as the dissolution medium, the rotation speed is 75 rpm, operate according to law, after 45 minutes, take the solution to filter, take the filtrate as the test solution; another gliquidone reference product, about 30mg, was precision weighed and dissolved by adding 10ml of N,N-dimethylformamide, and quantitatively diluted with dissolution medium to prepare a solution containing about 30ug per 1 ml as a reference solution. The absorbance of each of the above two Solutions was measured at a wavelength of 0401 NM according to ultraviolet-visible spectrophotometry (general), and the elution amount of each tablet was calculated. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).

Content determination

Take 10 tablets of this product, precision weighing, fine grinding, precision weighing appropriate amount (about 50mg equivalent to gliquidone), put it in a 100ml measuring flask, add about 70ml of methanol, dissolve gliquidone by ultrasound in water bath, let it cool, dilute to scale with methanol, shake well, filter, take 10ml continuous filtrate accurately and put it in 50ml measuring flask, dilute with methanol to the scale, shake, according to UV-visible spectrophotometry (General rule 0401), absorbance was measured at the wavelength of 310nm; Another gliquidone reference, precision weighing, methanol was added to dissolve and quantitatively diluted to make about 0.lmg solution, the same method for the determination, calculation, that is.

specification

30mg

storage

light shielding, sealed storage.

Last Update：2022-01-01 15:36:19

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide

Hefei TNJ Chemical Industry Co.,Ltd.

Product Name: Gliquidone Request for quotation
CAS: 33342-05-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
　　　　 info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840

Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog

Shanghai Yuanye Bio-Technology Co., Ltd.

Multiple SpecificationsSpot supply

Product Name: Gliquidone Visit Supplier Webpage Request for quotation
CAS: 33342-05-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Hefei TNJ Chemical Industry Co.,Ltd.

Product Name: Gliquidone Request for quotation
CAS: 33342-05-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
　　　　 info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840

Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog

Shanghai Yuanye Bio-Technology Co., Ltd.

Multiple SpecificationsSpot supply

Product Name: Gliquidone Visit Supplier Webpage Request for quotation
CAS: 33342-05-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide Request for Quotation

Gliquidone

CAS: 33342-05-1

Molecular Formula: C27H33N3O6S

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Names and Identifiers

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Physico-chemical Properties

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Risk and Safety

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Reference

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Standard

Authoritative Data Verified Data

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Trait

Authoritative Data Verified Data

melting point

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Differential diagnosis

Authoritative Data Verified Data

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Exam

Authoritative Data Verified Data

chloride

sulfate

Related substances

loss on drying

ignition residue

Heavy metals

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Content determination

Authoritative Data Verified Data

chromatographic conditions and system suitability test

assay

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Category

Authoritative Data Verified Data

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Storage

Authoritative Data Verified Data

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide - Gliquidone Tablets

Authoritative Data Verified Data

trait

identification

examination

Content determination

category

specification

storage

Supplier List

N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide